One dose of PD-1 blockade predicts melanoma outcome
Neoadjuvant treatment with pembrolizumab was effective in 30% of patients
The response to a single dose of neoadjuvant PD-1 (programmed cell death protein 1) blockade predicts clinical outcomes in patients with stage III or IV resectable melanoma, researchers report.
“The most important and interesting point was that a single dose can result in complete eradication of the tumour, and the immune effect can occur extremely rapidly (within 7 days),” said first author, Dr Alexander Huang from Perelman School of Medicine, University of Pennsylvania, USA.
